SSRIs, Dosage, Preparation, and More
*This event will be recorded
Are you interested in mushrooms for depression?
Whether you’ve received a diagnosis of depression or you are just seeking to feel better in your life, many people are looking to mushrooms as a potential solution. But it’s not as simple as just journeying. There’s a number of considerations from preparation to dosage, therapy versus ceremony, and integration. Mushrooms may be a powerful tool that catalyzes healing, but the intentionality behind them is often what influences whether their effects are long lasting. We discuss all this and more with Dr. Rosalind Watts, former Clinical Lead of the Psilocybin for Depression trial at Imperial College London, and Mikaela de la Myco, mushWOMB educator, researcher, and founder of Mothers of the Mushroom.
About Our Guests
Who is Mikaela de la Myco?
Mikaela de la Myco serves as a mother, mushWOMB educator, facilitator, researcher and eco-sensual in the plant medicine, womb care and ethics space. Supporting from Kumeyaay & Luiseño territories (San Diego, CA), she advocates for trauma-informed and earth-centered practices, filling in educational and service gaps in the wellness community.
She founded Mothers of the Mushroom, a citizen research project studying mothers who ingested psilocybin mushroom during pregnancy, breastfeeding, and postpartum and MAAT, a mutual aid initiative supporting survivors of harm in the wellness community. Her work has been featured in Microdosing for Health, Healing and Enhanced Performance, The Psilocybin Handbook for Women, and many other publications, podcasts and media outlets. In her collaboration with organizations, families, and practitioners across the psychedelic field, she is committed to being a dear friend and ally in the struggle to rematriate entheogens.
Who is Dr. Rosalind Watts?
As former Clinical Lead of the Psilocybin for Depression trial at Imperial College London, Rosalind Watts, PhD, led a clinical team which facilitated over a hundred psilocybin treatment sessions. She developed the ACE model for psychedelic-assisted therapy ‘Accept, Connect, Embody,’ which has been used in clinical trials of psilocybin and dmt. Having recognized that safe and effective use of psychedelics requires substantial integration support, Rosalind co-founded the UK’s first psychedelic integration group, and is now launching a global online integration community, ‘Accept, Connect, Embody, Restore’ (ACER) where members will follow a 12-month process together. She has developed a psychometric tool for measuring outcomes of psychedelic therapy (the Watts Connectedness Scale) is clinical track lead on the Synthesis Institute’s Psychedelic Practitioner Training, and sits on the clinical advisory board of the Usona Institute, a not-for-profit psilocybin manufacturer and research organization. Her website is drrosalindwatts.com.
Who is Shelby Hartman?
Moderator
Shelby Hartman is Co-Founder and Publisher of DoubleBlind, a media company at the forefront of the psychedelic movement. She’s reported for the Los Angeles Times, Rolling Stone, VICE, Playboy, Quartz, LA Weekly, and the Huffington Post, among others. Her work has been featured in outlets such as The New York Times, Business Insider, KCRW, Bustle, and Forbes, and she’s been invited to speak at SXSW, Horizons: Perspectives in Psychedelics, and Harvard Law School. She’s the co-author of The DoubleBlind Guide to Psychedelics (Hachette, 2026), a practical guide on how to trip situated within reporting about the psychedelic ecosystem. In 2020, she was named by Forbes as a female leader in cannabis and psychedelics. She’s a graduate of Columbia Journalism School.